These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24267160)

  • 1. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
    Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
    BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.
    Tanaka Y; Hatakeyama S; Hosogoe S; Tanaka T; Hamano I; Kusaka A; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Int J Clin Oncol; 2018 Feb; 23(1):134-141. PubMed ID: 28752352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney cancer: progress and controversies in neoadjuvant therapy.
    Posadas EM; Figlin RA
    Nat Rev Urol; 2014 May; 11(5):254-5. PubMed ID: 24752207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
    Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
    Sassa N; Kato M; Funahashi Y; Maeda M; Inoue S; Gotoh M
    Jpn J Clin Oncol; 2014 Apr; 44(4):370-3. PubMed ID: 24571808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib].
    Shimura S; Koguchi D; Minamida S; Taoka Y; Iwamura M
    Hinyokika Kiyo; 2017 Jan; 63(1):11-14. PubMed ID: 28245539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib].
    Ishizuya Y; Okusa T; Hatano K; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
    Hinyokika Kiyo; 2016 Oct; 62(10):525-528. PubMed ID: 27919126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report].
    Arai Y; Ito K; Tachi K; Koga A; Shinchi Y; Masunaga A; Isono M; Asano T
    Hinyokika Kiyo; 2016 Sep; 62(9):465-471. PubMed ID: 27760971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.
    Karam JA; Devine CE; Fellman BM; Urbauer DL; Abel EJ; Allaf ME; Bex A; Lane BR; Thompson RH; Wood CG
    BJU Int; 2016 Apr; 117(4):629-35. PubMed ID: 26033220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma.
    Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Tanaka Y; Hagiwara K; Hirai H; Morohashi S; Kijima H; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Oncotarget; 2017 Jul; 8(30):49749-49756. PubMed ID: 28572534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib controlled metastatic renal cell carcinoma for 5 years.
    Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S
    Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
    Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.